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A B S T R A C T
Objective: Recent years have witnessed an increased interest in the use of multicriteria decision analysis (MCDA) to support
health technology assessment (HTA) agencies for setting healthcare priorities. However, its implementation to date has been
criticized for being “entirely mechanistic,” ignoring opportunity costs, and not following best practice guidelines. This article
provides guidance on the use of MCDA in this context.
Methods: The present study was based on a systematic review and consensus development. We developed a typology of MCDA
studies and good implementation practice. We reviewed 36 studies over the period 1990 to 2018 on their compliance with good
practice and developed recommendations. We reached consensus among authors over the course of several review rounds.
Results: We identiﬁed 3 MCDA study types: qualitative MCDA, quantitative MCDA, and MCDA with decision rules. The types
perform differently in terms of quality, consistency, and transparency of recommendations on healthcare priorities. We advise
HTA agencies to always include a deliberative component. Agencies should, at aminimum, undertake qualitativeMCDA. The use
of quantitativeMCDA has additional beneﬁts but also poses design challenges. MCDAwith decision rules, used byHTA agencies
in The Netherlands and the United Kingdom and typically referred to as structured deliberation, has the potential to further
improve the formulation of recommendations but has not yet been subjected to broad experimentation and evaluation.
Conclusion:MCDA holds large potential to support HTA agencies in setting healthcare priorities, but its implementation needs
to be improved.
Keywords: HTA agencies, multicriteria decision analysis, priority setting, value framework.
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Introduction
Recent years have witnessed an increased interest in the use of
multicriteria decision analysis (MCDA) to support health tech-
nology assessment (HTA) agencies in setting healthcare prior-
ities.1-6 MCDA offers decision makers a structured way to include
the different values that society holds. The term values here refers
to both the therapeutic beneﬁts of a technology for patients and
their broader social impact.7,8 For example, decision makers may
value technologies that not only maximize population health
but also reduce health inequalities or protect people against the
impoverishing effects of ill health.9 However, the way that MCDA
has been implemented to date has been criticized for being
“entirely mechanistic,”10 ignoring opportunity costs,11,12 and
paying insufﬁcient attention to best practice guidelines.11-14 Sub-
sequently, some HTA agencies and scholars have rejected its
use.10,11,15,16
This article provides guidance on the use of MCDA by HTA
agencies. We present a typology of MCDA studies, a review of
studies over the period 1990 to 2018 for illustrative purposes, and
a critical assessment of the various study types (second through
ﬁfth sections). We judge the ability of the study types to improve
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the recommendations of HTA agencies, in terms of their quality
(by taking into account all relevant [stakeholder] values and
making appropriate trade-offs between them and by capturing
opportunity costs), their consistency (by repeatedly considering
the same values), and their transparency (by being explicit on the
selection of values and the performance of technologies on these
values).4,5,7 Together, this ultimately improves the legitimacy of
recommendations.7 Finally, we provide recommendations on the
use of MCDA in HTA decision making (see the “Discussion”
section).
This article addresses governmental HTA agencies but is also
relevant for countries that have not (yet) established such an
agency. We assume a model in which an agency has installed an
(appraisal) committee that formulates recommendations for the
Ministry of Health on technology coverage decisions. We consider
this task of HTA agencies as an intrinsically complex and value-
laden political process.17-21 Society, including relevant stake-
holders such as healthcare providers, patients, citizens, funders,
and decision makers, have different interests and may reasonably
disagree on what values should be used to guide priority setting.20
Because national governments are accountable to the populations
they serve, they should be concerned with establishing legitimate
decision-making processes that take these values into account.22
Stakeholder deliberation is considered an essential component
to achieve such legitimacy.7,20
The paper follows up on the recent ISPOR MCDA Emerging
Good Practices Task Force on the use of MCDA in healthcare4,5 by
being speciﬁc on its application to HTA. It is written by 23 MCDA
and HTA experts, and is the result of intensive discussions using
various review rounds. It can be considered as a consensus
statement on the beneﬁts and limitations of the use of MCDA for
HTA agencies, and its way forward.
A Typology of MCDA Studies
MCDA is deﬁned as “an umbrella term to describe a collection
of formal approaches which seek to take explicit account of
multiple criteria in helping individuals or groups exploring de-
cisions that matter.”4,23 Any MCDA involves at least 3 steps:
deﬁning the decision problem, selecting the criteria that reﬂect
relevant values, and constructing the performance matrix.4 The
performance matrix is a central element and, when applied to
HTA, typically includes a set of generic criteria that are relevant to
many technologies. The performance matrix presents an assess-
ment of each technology against each of these criteria using
descriptive information, such as natural units (eg, number of
deaths), categories (eg, targeted age group), summary measures of
health (eg, quality-adjusted life-years [QALYs]), or descriptive text
(eg, perceived role of own responsibility). (An example can be
found in Fig. 1.)24 The committee evaluates the performance ma-
trix before formulating a recommendation.24 They may rely on the
criteria included in the performance matrix and, if applicable,
include other considerations speciﬁc to the technology under
scrutiny.7
We distinguish “qualitative MCDA,” “quantitative MCDA,” and
“MCDA with decision rules,” depending on the way the perfor-
mance matrix is used. By reviewing the literature on the use of
MCDA in HTA between 1990 and 2018, we identiﬁed 36 studies
and classiﬁed these accordingly (review details are presented in
Appendix A in the Supplemental Materials found at https://doi.
org/10.1016/j.jval.2019.06.014). Our review identiﬁed 1 qualita-
tive MCDA study, 35 quantitative MCDA studies, and no studies
using MCDA with decision rules. We nevertheless included the
latter as a distinct study type because of its use by some HTA
agencies.
Qualitative MCDA
In qualitative MCDA, the committee makes a judgment on the
overall value of a technology by deliberating on its performance
regarding explicitly deﬁned criteria (ie, it makes a qualitative
interpretation of the performance matrix; Fig. 1).7 This approach is
also referred to as partial MCDA4,5 or the balance sheet method.25
The qualitative MCDA study included in our review pertains to
the development of the health beneﬁt package in Thailand.26
The distinctive feature of qualitative MCDA that makes it
different from intuitive prioritization (without any speciﬁc
method) is that it uses explicit criteria, including the technologies’
performance on these criteria. This has several implications for the
quality, consistency, and transparency of recommendations.
First, the use of explicit criteria improves the quality of recom-
mendations as it fosters in-depth consideration of the criteria,
including the available evidence, and it provides structure to
deliberative discussions of the committee.27 This arguably reduces
the committee’s cognitive load of simultaneously processing in-
formation on otherwise implicit criteria. However, the cognitive
load may still be extensive, especially when it involves the simul-
taneous evaluation of multiple technologies requiring complex
trade-offs between criteria. In addition, qualitative MCDA carries
the risk that certain stakeholders dominate the deliberations,
Figure 1. Interpretation of performance matrix in qualitative multicriteria decision analysis. Severity of disease is shown as a 4-star
scale, with more stars indicating a more severe disease.
Technologies
Antiretroviral treatment in
HIV/AIDS
Treatment of childhood
pneumonia
Inpatient care for acute
schizophrenia
Plastering for simple fractures
Criteria
Effectiveness
(quality adjusted
life years)
Severity of
disease
Disease
of the
poor
√
√
Age
100
200
200
10
15 years and older
15 years and older
0-14 years
all
Adapted from Baltussen R, et al.24
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especially in contexts with unbalanced power relation-
ships.24,25,27,28 This may reduce the quality of recommendations
unless mechanisms to minimize dominance are installed.29
Furthermore, it depends on the included criteria whether qualita-
tive MCDA facilitates a comparison with alternative uses of re-
sources and thereby captures opportunity costs.
Second, if the same set of explicit criteria is repeatedly used in
other evaluations, qualitative MCDA improves the consistency of
eventual recommendations. Yet this consistency can be limited
because a committee may judge the importance of criteria across
evaluations differently. This can be overcome by making the
argumentation underlying a recommendation explicit: as such,
these argumentations can be referred to, and applied, in the
formulation of recommendations on other technologies.
Third, the use of explicit criteria improves the transparency of
recommendations. Full transparency would also require that the
argumentation for making a recommendation is made public.
However, this may not always be feasible (eg, in countries with
limited tradition of transparency and accountability in public de-
cision making).
Quantitative MCDA
Quantitative MCDA (also labeled full MCDA4,5) uses a value
measurement model to interpret the performance matrix, fol-
lowed by deliberation. This approach includes 5 further steps, in
addition to the 3 steps described earlier to construct the perfor-
mance matrix.4 First, stakeholders’ preferences are elicited to
specify a value function for each criterion, which translates a
technology’s performance on that criterion into a score (eg, be-
tween 0 and 100). Second, stakeholders’ preferences regarding
the relative importance of criteria are measured using criterion
weights. Various preference elicitation techniques such as ana-
lytic hierarchy process or discrete-choice experiments are avail-
able for this.4,5 Group preferences are often modeled by taking
the mean criterion weights and scores across respondents. Third,
a so-called value measurement model is used, which typically
multiplies scores by the relative weight of that criterion, to sum
the weighted scores and obtain an overall value for each tech-
nology. Technologies are ranked on the basis of these overall
values (an example is provided in Fig. 2).4,5 Fourth, uncertainty
analysis is performed to understand the level of robustness of the
results. Fifth, the committee deliberates on this rank ordering of
technologies, allowing a ﬂexible interpretation of the results; that
is, its members can put forward and discuss (aspects of) criteria
that were not (fully) captured in the performance matrix (eg, on
complex consideration such as “own responsibility”). This step
may lead to changes in the ordering of technologies. With 35
studies, quantitative MCDA is the most common study type in our
review.
Quantitative MCDA has several beneﬁts in comparison to
qualitative MCDA. First, the use of a value measurement model
reduces the cognitive load of processing several criteria simulta-
neously and the risk of dominant participants inﬂuencing the
deliberations. These aspects further contribute to the quality of
recommendations. Second, the use of criteria scores and weights
further improves the consistency of recommendations, if these
scores and weights are also used for the evaluation of
other technologies. Third, when these aspects are also commu-
nicated to the public, it further enhances the transparency of
recommendations.
These beneﬁts of using explicit weights are especially relevant
for HTA agencies in certain contexts. If an agency operates in a
country with limited tradition of transparency and accountability
in public decision making, this may raise trust in its decision
making. Also, the use of quantitative MCDA can be instrumental if
an agency operates in a country with a backlog of technologies
waiting for appraisal and insufﬁcient HTA capacity for more
detailed evaluations. We here refer to the case of the Colombian
HTA agency in 2012 to 2013, which faced the task of assessing
hundreds of technologies with very limited capacity.30
There are also various limitations to quantitative MCDA, which
typically relate to its implementation rather than fundamental
problems (for an overview of limitations by study, see Appendix
Table A1 in the Supplemental Materials) and which may
compromise the quality of recommendations. Here we focus on 5
of them. First, although quantitative MCDA should always include
a deliberative component allowing a committee to make a ﬂexible
interpretation of results, only 10 out of 35 studies reported such a
deliberation. This has likely led to the neglect of additional con-
siderations that are speciﬁc to the technology under scrutiny and,
subsequently, confounded recommendations. This suboptimal
practice seems to have led HTA agencies in the United Kingdom
and The Netherlands to explicitly reject quantitative MCDA. An
expert meeting conducted by the National Institute for Health and
Care Excellence (NICE) in the United Kingdom in 2012 concluded,
The majority of participants agreed that once the committee has
decided what the plausible incremental cost-effectiveness ratio is, the
decision-making process should remain deliberative and ﬂexible, rather
Figure 2. Interpretation of performance matrix in quantitative multicriteria decision analysis. Preference scores for effectiveness are
related to its values, following a linear scale. For disease of the poor, if the technology targets a disease of the poor, it scores 100,
otherwise 0. Preference scores for severity of disease are scaled between 0 and 100 in proportion to their bullets in the table. Assuming
decision-makers have a preference to treat young people over old, 0 to 14 years receives a score of 100, 15 years and older a score of 0,
and all ages a score of 50. Preference scores are presented here for illustrative purposes only and are arbitrary.
Technologies
Antiretroviral treatment in
HIV/AIDS
Treatment of childhood
Pneumonia
Inpatient care for acute
Schizophrenia
Plastering for simple fractures
Effectiveness Severity of
disease
Disease of 
the poor
Age
100100
100 100 100
0
0
0
10
0
40
100
50
50
50
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7
25
5
100
100
1040
Overall value
Weights
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than moving towards a fully quantitative (or algorithmic) approach. . . .
The vast majority of participants did not recommend that NICE should
attempt to assign weights to the additional criteria, suggesting that
ﬂexible deliberation is important rather than stringent rule.(...)16,31
An expert meeting in The Netherlands, organized by the Na-
tional Health Care Institute (ZIN) in 2015, drew a similar conclu-
sion, arguing that deliberation should always be part of its process
to formulate recommendations.15
Of the 10 studies that did include deliberation, this component
changed the initial rank order of technologies in only 3 studies.
This suggests that end users agree with the results from the value
measurement model or that they rely solely on its results.28 If the
latter is true, this indicates the need to organize adequate delib-
erative components in quantitative MCDA.
Second, 25 out of 35 studies used an additive value measure-
ment model, which embeds the preferential independence
assumption (ie, how people appreciate performance on one cri-
terion does not depend on the performance on other
criteria).12,13,28 This assumption does not always hold. For
example, a technology that does not improve population health
has no value, irrespective of whether it targets a severe or rare
disease. This is illustrated by a quantitative MCDA on anticancer
drugs in South Korea, in which stakeholders assigned a weight of
22% to the criterion “clinical beneﬁt.”32 It demonstrates that a
technology that is ineffective but performs well on all other
criteria can still obtain a high value. Whereas quantitative MCDA
would label this technology as high priority, it is clearly inap-
propriate. Value measurement models could include interaction
weights between criteria, but measuring these requires complex
elicitation approaches that are cognitively demanding.
Third, 29 of 36 studies included costs as a criterion in their
value measurement model and subsequently applied the “maxi-
mizing value” allocation rule. Here, the aggregate value of a
technology (ie, derived from the value functions of the individual
criteria) includes the value of the related costs (derived from the
value function of the cost criterion, in which higher costs are
related to lower values). Technologies with the highest overall
value are then considered priorities. The approach requires re-
spondents to derive value functions for all criteria including the
cost criterion and provide weights for the value function of cost in
relation to that of the other criteria. However, in practice, it is
unrealistic to assume that individuals can adequately fulﬁll this
task. It is unlikely that they are aware of health budget constraints
and alternative ways of using resources, and their responses
therefore do not adequately capture the opportunity costs of al-
ternatives.5,12,33 This may result in a confounded ranking of
technologies (see Appendix B in the Supplemental Materials for a
numerical example).
For this reason, several authors have instead proposed the
use of the traditional “cost-per-value” allocation rule.5,12,34
Here, the costs of a technology are divided by the aggregate
value of other criteria. Subsequently, technologies are rank
ordered on the basis of their cost-per-value ratio, and tech-
nologies with the lowest ratios are considered priorities. To
achieve an optimal allocation of resources and adequately take
into account opportunity costs, HTA agencies are then advised
to fund technologies according to this ranking until the budget
is exhausted. Or, as an alternative approach, the cost-per-value
of a technology can be compared with a threshold. However,
in reality, budget constraints are seldom explicit, and cost-per-
value thresholds are typically unknown.35 This means that
quantitative MCDA can provide only a ranking of technologies
and cannot be explicit on whether technologies are providing
value for money. This approach may, in the absence of
recognition of opportunity costs, result in a suboptimal allo-
cation of resources.
Closely related, 20 studies included “cost-effectiveness,” such
as cost per QALY, as a criterion in the value measurement model.
The approach requires respondents to derive a value function and
weights for the cost-effectiveness criterion in relation to that of
the other criteria, thereby reﬂecting the opportunity costs of al-
ternatives. As reasoned earlier, it is unrealistic to assume that in-
dividuals can adequately perform this task.
Fourth, 25 out of 35 studies involved double counting of 1 or
more criteria. This indicates problems in the structuring phase of
the MCDA value measurement model.36
Fifth, 2 out of 35 studies did not use preference-based tech-
niques such as an analytic hierarchy process or discrete-choice
experiments for eliciting scores and weights but applied simple
direct rating methods such as point allocation. These studies risk
eliciting scores and weights that are subject to framing bias, as
criteria and their performance ranges are not explicitly traded
off.12 In addition, these studies often provide no or only qualitative
descriptions of performance ranges, and respondents may inter-
pret these ranges differently.12
MCDA With Decision Rules
In MCDA with decision rules, the committee interprets the
performance matrix with a set of simple rules. These rules guide
them in making trade-offs between criteria, which can be quanti-
tative or qualitative in nature. Some HTA agencies follow this
approach, deﬁning the relationship between cost-effectiveness and
other criteria. For example, ZIN in The Netherlands appraises the
cost-effectiveness of technologies in relation to the severity of the
condition. Technologies that targetmild conditions (ie, below0.4 on
a burden of disease scale from 0 to 1) should cost less thanV20 000
per QALY to receive an initial positive recommendation for reim-
bursement. Technologies targeting severe and very severe condi-
tions (ie, between 0.4 and 0.7 and greater than 0.7) may cost up to
V50 000 and V80 000 per QALY, respectively. Subsequently, ZIN
evaluates in a deliberative process whether other criteria affect the
initial recommendation and reaches a ﬁnal recommendation.37 In
the United Kingdom, NICE has issued decision rules on the rela-
tionship between cost-effectiveness and other criteria:
Above a most plausible ICER [incremental cost-effectiveness ratio] of
£20,000 per QALY gained, judgements about the acceptability of the
technology as an effective use of NHS resources will speciﬁcally take
account of the following factors: The degree of certainty around the
ICER . . . , the innovative nature of the technology . . . , the technology
meets the criteria for special consideration as a ‘life-extending treat-
ment at the end of life’ . . . , and aspects that relate to non-health ob-
jectives of the NHS.38
In its highly specialized technology program for very rare
diseases, NICE raised the threshold to £100 000 to £300 000
per QALY gained. This increased threshold reﬂects the fact that
NICE assigns a quantitative weight to the treatment of these
diseases.39
We label the NICE and ZIN approaches as MCDA, whereas we
acknowledge that they are usually referred to as structured
deliberation.37,38 We do so as the approaches ﬁt within the
MCDA deﬁnition, as provided earlier, to “take explicit account of
multiple criteria in helping individuals or groups exploring de-
cisions that matter.” We hereby wish to bridge the artiﬁcial gap
between so-called deliberative and MCDA approaches and to
stimulate the debate on how multiple criteria can best be taken
into account.
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How does MCDA with decision rules compare with quantita-
tive MCDA? First, the approach can incorporate the principle of
opportunity costs, if cost-effectiveness is used as a central crite-
rion and its threshold is known. It therefore improves on quan-
titative MCDA, which does not capture opportunity costs and
could therefore be considered less suitable for priority setting.
Second, the approach as applied by ZIN and NICE includes only a
limited number of criteria in its decision rules. This contrasts with
the multiple (often 10 or more) criteria that are typically included
in quantitative MCDA. Although this is not a necessary difference
between the MCDA designs, experience so far indicates that this
allows MCDA with decision rules to more rigorously deﬁne and
assess the most important criteria. A disadvantage is that MCDA
with decision rules may involve more deliberation around the
remaining criteria that are not included in decision rules. Delib-
eration can take more time than value measurement and may also
lead to less consistent and transparent recommendations if not
well documented.
Discussion
The core challenge for HTA agencies is to optimize the quality,
consistency, and transparency of their recommendations for pri-
ority setting. This article shows that various MCDA types perform
differently with regard to these aspects. Here, we provide rec-
ommendations for HTA agencies and the research community on
the future use of MCDA types.
First, we advise HTA agencies to always include a deliberative
component in their process of formulating recommendations. This
allows the relevant committee a ﬂexible interpretation of
decision-making criteria to take into account all possible consid-
erations that matter. Such deliberation may improve the quality of
recommendations. Agencies should report these deliberations,
including the considerations underlying a recommendation, to
ensure the consistency and transparency of recommendations.
Second, agencies should, at a minimum, undertake qualitative
MCDA. The use of explicit criteria improves the quality, consis-
tency, and transparency of recommendations as compared with
employing no speciﬁc method at all, although important chal-
lenges remain.
Third, HTA agencies may consider the use of quantitative
MCDA. A number of HTA agencies have already implemented
this approach40,41 but base their recommendations on the value
measurement model only. We recommend that they work to-
ward the incorporation of deliberative elements into their
MCDA designs in the future. Quantitative MCDA also poses other
design challenges. Speciﬁcally, we advise researchers not to
include “cost” or “cost-effectiveness” as criteria in the value
measurement model. More generally, we advise researchers to
follow good practice and indicate the potential confounding that
stems from suboptimal designs.4 HTA agencies should be aware
of these challenges when interpreting the results. They should
also be aware that quantitative MCDA does not capture oppor-
tunity costs and may thus lead to a suboptimal allocation of
resources.
Fourth, HTA agencies may consider the use of MCDA with de-
cision rules. This approach has the same potential as quantitative
MCDA to improve decision making, but depending on the included
number of criteria, may rely more on deliberation. It also avoids
certain challenges in study design and can capture opportunity
costs. The approach is now routinely used in The Netherlands and
the United Kingdom (albeit named differently), and this demon-
strates it is workable in practice. However, it has not been sub-
jected to broad experimentation and evaluation, and we call for
research to demonstrate the added value of MCDA with decision
rules.
Fifth, HTA agencies should ensure that the speciﬁcation of
MCDA (ie, in terms of value measurement model or decision rules)
is legitimate and reﬂects societal preferences. The debate in
the United Kingdom on a proposed “value-based assessment”
framework demonstrates this challenge.42,43 This article has not
discussed how to best elicit stakeholder preferences, and we call
for further debate and guidance on this topic.
This article makes a signiﬁcant contribution to the literature
on the use of MCDA in HTA. It follows up on the ISPOR MCDA
Emerging Good Practices Task Force on the use of MCDA in
healthcare4,5 by providing guidance on its speciﬁc application to
HTA. In addition, it provides a head-to-head comparison of the
different MCDA study types, identifying the options and limita-
tions of each approach, and providing recommendations on its
use by HTA agencies. We thereby deﬁne MCDA with decision
rules as a separate MCDA study type, although this approach is
typically referred to as “structured deliberation,” and our review
did not identify any such study. We nevertheless did so to
stimulate the debate on how multiple criteria can best be taken
into account.
Our recommendations should be interpreted in the context of
the following aspects. First, our literature review includes only
studies that are self-described MCDA. Many other studies exist
that do consider multiple criteria but are not labeled as such. This
may explain the small number of studies found, with most of them
focusing on quantitative MCDA, only one on qualitative MCDA,
and none on MCDA with decision rules. Our literature review
should then also be considered as illustrative only. Second, we
evaluate MCDA study types on their ability to improve the quality
of recommendations. With our deﬁnition of quality, we aim to
identify and differentiate the most important options and limita-
tions of the study types. The deﬁnition is not meant to capture all
aspects of quality of decision making (eg, quality of evidence or
quality of stakeholder deliberation). Third, we evaluated study
types in terms of transparency of forthcoming recommendations,
but HTA agencies or involved stakeholders may not always aim for
full transparency of their reimbursement recommendations (eg, in
the case of price negotiations with providers). Fourth, in the re-
ality of healthcare priority setting (in which decisions on tech-
nologies are typically taken for single technologies), we argue that
quantitative MCDA cannot capture opportunity costs. However,
in speciﬁc circumstances in which decisions are made for a
complete set of technologies in the presence of a ﬁxed budget,
mathematical programming techniques can be used to develop
optimal solutions.
In conclusion, MCDA holds large potential to support HTA
agencies in formulating high-quality, consistent, and transparent
recommendations. However, its application has often been inad-
equate and subject to criticism. We consider it the shared re-
sponsibility of HTA agencies, the research community, and
decision makers to improve on the use of MCDA, to realize its full
potential.
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